A股異動丨康泰生物(300601.SZ)反彈逾7% 阿斯利康新冠肺炎疫苗試驗或在下週恢復
格隆匯9月10日丨受阿斯利康暫停新冠疫苗臨牀試驗牽連,康泰生物(300601.SZ)崩跌16.57%,股價創2個月新低。康泰生物董祕昨日迴應稱,阿斯利康是全球新冠疫苗研發的公司中較為領先的,試驗規模最大,出現個別案例是研發中的正常現象,不影響公司與阿斯利康合作的推進。另外,有消息稱阿斯利康的新冠肺炎疫苗試驗可能在下週恢復;其新冠肺炎疫苗試驗參與者可能會在9月9日出院。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.